Search
Nafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSegesterone acetate
go.drugbank.com/drugs/DB14583ApprovedSegesterone acetate is not an orally active compound, but it is proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel [A37090]. … On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S.
Categories: Hormonal Contraceptives for Systemic UseMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalIt received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. … [A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471]
Delafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalIt was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseResorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalResorcinol works by helping to remove hard, scaly, or roughened skin. … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Categories: Anti-Acne Preparations for Topical UseAzacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigational[A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … [A1407,A1410,A1411,A1416,A1417] In May 2004, the FDA approved the use of azacitidine administered subcutaneously for the treatment of MDS of all French-American-British (FAB) subtypes.
Pivmecillinam
go.drugbank.com/drugs/DB01605ApprovedInvestigationalPivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseQuaternium-15
go.drugbank.com/drugs/DB14198ApprovedIn 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … It is an anti-microbial agent by virtue of being a formaldehyde releaser, however this can also cause contact dermatitis, a symptom of an allergic reaction, especially in those with sensitive skin.
Mixtures: Test Thin-Layer Rapid Use Patch TestClofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalIts potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnLigand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA. … It gained approval by European Commission in March 2009.